Fear of hypoglycemia in children with type 1 diabetes and their parents: Effect of pump therapy and continuous glucose monitoring with option of low glucose suspend in the CGM TIME trial.
continuous glucose monitoring
fear of hypoglycemia
pump therapy
type 1 diabetes
Journal
Pediatric diabetes
ISSN: 1399-5448
Titre abrégé: Pediatr Diabetes
Pays: Denmark
ID NLM: 100939345
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
09
07
2020
revised:
27
10
2020
accepted:
29
10
2020
pubmed:
13
11
2020
medline:
11
1
2022
entrez:
12
11
2020
Statut:
ppublish
Résumé
To determine if pump therapy with continuous glucose monitoring offering low glucose suspend (LGS) decreases fear of hypoglycemia among children with type 1 diabetes and their parents. The CGM TIME trial is a multicenter randomized controlled trial that enrolled 144 children with type 1 diabetes for at least 1 year (mean duration 3.4 ± 3.1 years) starting pump therapy (MiniMed™ Veo™, Medtronic Canada). CGM (MiniMed™ Enlite™ sensor) offering LGS was introduced simultaneously or delayed for 6 months. Hypoglycemia Fear Scale (HFS) was completed by children ≥10 years old and all parents, at study entry and 12 months later. Simultaneous and Delayed Group participants were combined for all analyses. Subscale scores were compared with paired t-tests, and individual items with paired Wilcoxon tests. Linear regression examined association with CGM adherence. 121/140 parents and 91/99 children ≥10 years had complete data. Mean Behavior subscale score decreased from 21.1 (SD 5.9) to 17.2 (SD 6.1) (p < .001) for children, and 20.7 (SD 7.5) to 17.4 (7.4) (p < .001) for parents. Mean Worry subscale score decreased from 17.9 (SD 11.9) to 11.9 (SD 11.4) (p < .001) for children, and 23.1 (SD 13.2) to 17.6 (SD 10.4) (p < .001) for parents. Median scores for 10/25 child items and 12/25 parent items were significantly lower at 12 months (p < .001). Linear regression found no association between HFS scores and CGM adherence. Insulin pump therapy with CGM offering LGS significantly reduced fear of hypoglycemia not related to CGM adherence in children with type 1 diabetes and their parents.
Identifiants
pubmed: 33179818
doi: 10.1111/pedi.13150
pmc: PMC7983886
doi:
Substances chimiques
Hypoglycemic Agents
0
Insulin
0
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
288-293Subventions
Organisme : Juvenile Diabetes Research Foundation
ID : 80-2010-585
Pays : United States
Informations de copyright
© 2020 The Authors. Pediatric Diabetes published by John Wiley & Sons Ltd.
Références
Diabetes Technol Ther. 2013 Aug;15(8):622-7
pubmed: 23883408
Diabetes Care. 2014;37(5):1224-9
pubmed: 24757229
Pediatr Diabetes. 2021 Mar;22(2):279-287
pubmed: 33098212
JAMA. 2013 Sep 25;310(12):1240-7
pubmed: 24065010
N Engl J Med. 2013 Jul 18;369(3):224-32
pubmed: 23789889
Diabetes Care. 2014 Jul;37(7):1885-91
pubmed: 24804697
J Pediatr Psychol. 2014 Nov-Dec;39(10):1115-25
pubmed: 25214644
Diabetes Educ. 1997 May-Jun;23(3):281-6
pubmed: 9257618
J Pediatr Endocrinol Metab. 1998 Mar;11 Suppl 1:189-94
pubmed: 9642659
BMC Pediatr. 2010 Jul 15;10:50
pubmed: 20633252
BMC Pediatr. 2014 Jul 18;14:183
pubmed: 25034216
Diabetes Care. 2014;37(3):773-9
pubmed: 24170766
Pediatr Diabetes. 2021 Mar;22(2):288-293
pubmed: 33179818
Diabetes Care. 2012 Jul;35(7):1462-5
pubmed: 22584133
Diabetes Care. 1987 Sep-Oct;10(5):617-21
pubmed: 3677982
Diabet Med. 2013 Sep;30(9):1126-31
pubmed: 23808967
Diabetes Care. 2015 Jul;38(7):1197-204
pubmed: 26049549